Lupin's trandolapril tablets are the AB-rated generic equivalent of Abbott's Mavik tablets, indicated for the treatment of hypertension. The brand product had annual sales of approximately $49 million for the twelve months ended December 2006, based on IMS sales data.
Commenting on the approval, Vinita Gupta, president and MD of Lupin Pharmaceuticals, said: “This approval broadens our growing portfolio of cardiovascular medications, and we look forward to offering this cost-effective alternative to patients in the US.”